High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma

J Am Acad Dermatol. 2018 Jul;79(1):165-167.e2. doi: 10.1016/j.jaad.2018.03.006. Epub 2018 Mar 12.
No abstract available

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Analysis of Variance
  • Biomarkers, Tumor / blood
  • Cohort Studies
  • Female
  • France
  • Humans
  • Immunotherapy / methods*
  • Lymphocyte Count
  • Lymphocytes / cytology
  • Male
  • Melanoma / drug therapy*
  • Melanoma / mortality*
  • Melanoma / pathology
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Invasiveness / pathology
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Neutrophils / cytology
  • Patient Selection
  • Prognosis
  • Programmed Cell Death 1 Receptor / administration & dosage*
  • Retrospective Studies
  • Risk Assessment
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / mortality*
  • Skin Neoplasms / pathology
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Programmed Cell Death 1 Receptor